Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
10:30am, Friday, 18'th Jul 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?
04:47am, Friday, 18'th Jul 2025
The active ingredients of roughly 80% of prescription drugs sold in the U.S. are made in other countries. President Trump wants that to change.
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
10:46am, Thursday, 17'th Jul 2025
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
01:19pm, Wednesday, 16'th Jul 2025
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025)
10:10am, Monday, 14'th Jul 2025
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:00am, Monday, 14'th Jul 2025
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Dividend Growth Stocks to Buy and Hold
06:40am, Saturday, 12'th Jul 2025
What's better than a great dividend? A great dividend that's growing.
Orr: PLTR & NVDA are Overvalued, GOOGL & LLY Great Upcoming Picks
03:30pm, Friday, 11'th Jul 2025
Steven E. Orr finds Palantir (PLTR) overvalued right now and is looking for it to pull back to $100/share. He feels the same about Nvidia (NVDA), citing market FOMO.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
09:56am, Friday, 11'th Jul 2025
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Eli Lilly Comes Out As ADA Winner
04:31pm, Thursday, 10'th Jul 2025
Eli Lilly reported impressive data from bimagrumab and eloralintide programs, reinforcing its leadership in obesity therapeutics. Results from competitors were either as expected or underwhelming. Fav
The Big 3: AVGO, LLY, UBER
12:35pm, Thursday, 10'th Jul 2025
Joe Tigay joins today's Big 3 and turns to three stocks that he believes investors should keep on their radar as the market "broadens." He talks about the potential for Broadcom (AVGO) to continue its
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
11:11am, Thursday, 10'th Jul 2025
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Thursday, 10'th Jul 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
06:46pm, Wednesday, 09'th Jul 2025
In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
03:27pm, Wednesday, 09'th Jul 2025
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable
